Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma
2015 | journal article; research paper. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma
Reichwagen, A.; Ziepert, M.; Kreuz, M.; Gödtel-Armbrust, U.; Rixecker, T.; Poeschel, V. & Toliat, M. R. et al. (2015)
Pharmacogenomics, 16(4) pp. 361-372. DOI: https://doi.org/10.2217/PGS.14.179
Documents & Media
Details
- Authors
- Reichwagen, Annegret; Ziepert, Marita; Kreuz, Markus; Gödtel-Armbrust, Ute; Rixecker, Tanja; Poeschel, Viola; Toliat, Mohammad Reza; Nürnberg, Peter; Tzvetkov, Mladen ; Deng, Shiwei; Trümper, Lorenz ; Hasenfuss, Gerd ; Pfreundschuh, Michael; Wojnowski, Leszek
- Abstract
- Aim: To identify gene variants responsible for anthracycline-induced cardiotoxicity. Patients & methods: Polymorphisms of the NADPH oxidase subunits and of the anthracycline transporters ABCC1, ABCC2 and SLC28A3 were genotyped in elderly patients (61-80 years) treated for aggressive CD20(+) B-cell lymphomas with CHOP-14 with or without rituximab and followed up for 3 years. Results: The accumulation of RAC2 subunit genotypes TA/AA among cases was statistically significant upon adjustment for gender, age and doxorubicin dose in a multivariate logistic regression analysis (OR: 2.3, p = 0.028; univariate: OR: 1.8, p = 0.077). RAC2 and CYBA genotypes were significantly associated with anthracycline-induced cardiotoxicity in a meta-analysis of this and a similar previous study. Conclusion: Our results support the theory that NADPH oxidase is involved in anthracycline-induced cardiotoxicity.
- Issue Date
- 2015
- Journal
- Pharmacogenomics
- ISSN
- 1462-2416
- eISSN
- 1744-8042
- Language
- English
